The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients.
Computational biology and bioinformatics
Epidemiology
Viral infection
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
01
2021
accepted:
31
08
2021
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
25
1
2022
Statut:
ppublish
Résumé
Persistence of antibodies to SARS-CoV-2 viral infection may depend on several factors and may be related to the severity of disease or to the different symptoms. We evaluated the antibody response to SARS-CoV-2 in personnel from 9 healthcare facilities and an international medical school and its association with individuals' characteristics and COVID-19 symptoms in an observational cohort study. We enrolled 4735 subjects (corresponding to 80% of all personnel) for three time points over a period of 8-10 months. For each participant, we determined the rate of antibody increase or decrease over time in relation to 93 features analyzed in univariate and multivariate analyses through a machine learning approach. Here we show in individuals positive for IgG (≥12 AU/mL) at the beginning of the study an increase [ SARS-CoV-2 infection induces a long lasting antibody response that increases in the first months, particularly in individuals with anosmia/dysgeusia. This may be linked to the lingering of SARS-CoV-2 in the olfactory bulb.
Sections du résumé
BACKGROUND
BACKGROUND
Persistence of antibodies to SARS-CoV-2 viral infection may depend on several factors and may be related to the severity of disease or to the different symptoms.
METHODS
METHODS
We evaluated the antibody response to SARS-CoV-2 in personnel from 9 healthcare facilities and an international medical school and its association with individuals' characteristics and COVID-19 symptoms in an observational cohort study. We enrolled 4735 subjects (corresponding to 80% of all personnel) for three time points over a period of 8-10 months. For each participant, we determined the rate of antibody increase or decrease over time in relation to 93 features analyzed in univariate and multivariate analyses through a machine learning approach.
RESULTS
RESULTS
Here we show in individuals positive for IgG (≥12 AU/mL) at the beginning of the study an increase [
CONCLUSIONS
CONCLUSIONS
SARS-CoV-2 infection induces a long lasting antibody response that increases in the first months, particularly in individuals with anosmia/dysgeusia. This may be linked to the lingering of SARS-CoV-2 in the olfactory bulb.
Identifiants
pubmed: 35072166
doi: 10.1038/s43856-021-00032-0
pii: 32
pmc: PMC8767777
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing interests.
Références
Asia Pac J Public Health. 2021 Jan;33(1):126-128
pubmed: 33242979
Lancet Reg Health Eur. 2021 May;4:100098
pubmed: 33969335
J Clin Invest. 2021 Jun 15;131(12):
pubmed: 33956667
Pediatr Infect Dis J. 2021 Aug 1;40(8):e294-e299
pubmed: 34250968
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Neuroscientist. 2021 Dec;27(6):582-603
pubmed: 32914699
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Front Med (Lausanne). 2021 Jun 17;8:653630
pubmed: 34222275
Sci Adv. 2020 Jul 31;6(31):
pubmed: 32937591
Cell Rep. 2021 Aug 10;36(6):109518
pubmed: 34358460
J Clin Immunol. 2021 Oct;41(7):1490-1501
pubmed: 34273064
Sci Transl Med. 2021 Jun 2;13(596):
pubmed: 33941622
Neurology. 2020 Aug 4;95(5):224-225
pubmed: 32444492
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Sci Rep. 2021 Jun 10;11(1):12312
pubmed: 34112899
Eur Respir J. 2020 Sep 24;56(3):
pubmed: 32817004
JAMA Neurol. 2020 Aug 1;77(8):1028-1029
pubmed: 32469400
Euro Surveill. 2021 Feb;26(6):
pubmed: 33573712
Nat Commun. 2020 Oct 14;11(1):5152
pubmed: 33056983
Pathogens. 2021 Jun 04;10(6):
pubmed: 34199852
ACS Chem Neurosci. 2020 Jun 3;11(11):1555-1562
pubmed: 32379417
Nat Commun. 2021 Aug 6;12(1):4740
pubmed: 34362897
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Otolaryngol Head Neck Surg. 2020 Nov;163(5):923-925
pubmed: 32513065
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
J Intern Med. 2020 Sep;288(3):335-344
pubmed: 32352202
Eur J Neurol. 2021 Jan;28(1):e6-e8
pubmed: 32939911